CAS: 2086772-26-9

JNJ-64619178

JNJ-64619178: selective, oral, pseudo-irreversible PRMT5 inhibitor (IC50: 0.14 nM), effective in lung cancer.

JNJ-64619178 is a novel small molecule that targets the methyltransferase domain of the protein PRMT5. The compound has been shown to induce apoptosis in cancer cells, and is currently being evaluated for safety and efficacy in clinical trials. This drug has been shown to have a favorable safety profile and shows no adverse effects on erythropoiesis. JNJ-64619178 is an investigational drug that belongs to the class of compounds that bind to the target site on PRMT5, which is involved in regulating gene expression. It binds to enzymes with methyltransferase activity and inhibits RNA splicing, leading to cell death by apoptosis.